Work

Reply to Glycemic Index/Load Effect on ALS Progression: Potential Interaction with Riluzole

Year: 2024

Type: letter

Abstract: The ALS COSMOS Study Group focused on the effect of baseline glycemic index/load on the rate of Revised Amyotrophic Lateral Sclerosis Functional Rating Scale total score from baseline. 1 This research is critical to developing the clinical trial calculus required to evaluate treatments in short-term 3/6 month phase 2b platform trials.The observational cohort was balanced among fast/slow progressors and riluzole use.Riluzole pharmacology shows enhancement of glucose transport in muscle/nerve cells in vitro, and increased cerebral glucose metabolism in animals, Alzheimer's disease, and Huntington's disease in vivo.2,3 Riluzole has been shown to decrease the rate of weight loss in fast amyotrophic lateral sclerosis (ALS) progressors.4 The interaction of riluzole pharmacology with glucose metabolism raises the following questions:

Source: Annals of Neurology

DOI: 10.1002/ana.26971